Treatment Response and Remission in a Double-Blind, Randomized, Head-to-Head Study of Lisdexamfetamine Dimesylate and Atomoxetine in Children and Adolescents with Attention-Deficit Hyperactivity Disorder
Ralf W Dittmann, Esther Cardo, Peter Nagy, Colleen S Anderson, Ben Adeyi, Beatriz Caballero, Paul Hodgkins, Richard Civil, David R Coghill
CNS DRUGS | ADIS INT LTD | Published : 2014
This study was supported by funding from Shire. The authors thank the patients and their parents, and the investigators who took part in the study. Esther Cardo, David R. Coghill, Ralf W. Dittmann and Peter Nagy were principal investigators in this clinical study. Colleen S. Anderson, Beatriz Caballero, Richard Civil, Ralf W. Dittmann and Paul Hodgkins contributed to the study design. Ben Adeyi was responsible for the statistical analysis. All authors were involved in the discussion and interpretation of the data, critically revised the article and approved the manuscript before submission. Dr Tamzin Gristwood and Dr Eric Southam of Oxford PharmaGenesis (TM) Ltd provided writing and editing assistance, collated the comments of the authors and edited the manuscript for submission, with funding from Shire. Ben Adeyi, Colleen S. Anderson and Beatriz Caballero are employees of Shire and own stock/stock options. Richard Civil is a former employee of Shire. Paul Hodgkins is a former employee of Shire and a current employee of Vertex Pharmaceuticals. The following authors have received compensation for serving as consultants or speakers, or they, or the institutions they work for, have received research support or royalties from the companies or organizations indicated: Esther Cardo (Eli Lilly, Health Spanish Ministry Research Fund, Ministry of Education Grant Research, Shire, UCB); David R. Coghill (Flynn Pharma, Janssen-Cilag, Lilly, Medice, Novartis, Otsuka, Oxford University Press, Pfizer, Schering-Plough, Shire, UCB, Vifor Pharma); Ralf W. Dittmann (Ferring, Janssen-Cilag, Lilly, Otsuka, Shire, German Research Foundation [DFG], German Ministry of Education and Research [BMBF], Ministry of Health/German Regulatory Body [BfArM], European Union [EU FP7 program], US National Institute of Mental Health (NIMH), and he is a former employee and stock-holder of Eli Lilly and Co.); Peter Nagy (Tourette Syndrome Association of USA, Hungarian Ministry of Education, National Development Agency of Hungary, Otsuka, Shire).